Lower Limb PAD — Disabling Intermittent Claudication Persisting After Walking-Improvement Pharmacotherapy
This protocol addresses patients with lower limb peripheral arterial disease and intermittent claudication (Rutherford grade I–III / Fontaine stage IIa–IIb) in whom walking-improvement pharmacotherapy has not achieved the required improvement in walking distance.
The clinical picture: exertional leg pain involving the calf, thigh, or buttock — not present at rest, not relieved during continued walking, and resolving within 10 minutes of stopping activity. Symptoms are classified as intermittent claudication at Fontaine stage IIa or IIb.
Previous treatment did not meet its goals
Walking-improvement pharmacotherapy — cilostazol or naftidrofuryl oxalate, added to best medical treatment and supervised exercise therapy — was trialled to improve maximum and pain-free walking distance. When reassessed at three to six months, the required improvement in walking distance was not reached, triggering escalation to the next protocol step.
Next clinical step
In carefully selected, compliant patients with continued disabling claudication, revascularisation is the next step — with the specific approach chosen according to the anatomical location of the lesion.
The full protocol specifies which revascularisation strategy applies at each anatomical site. The clinical goal is relief of disabling claudication, improved maximum walking distance, and better health-related quality of life.
References
DOI: 10.1016/j.ejvs.2023.08.067
- atherosclerotic lower extremity peripheral arterial disease (PAD, see also section 2.1) falling within the following clinical stages: (1) asymptomatic lower limb PAD (Rutherford grade 0/Fontaine stage I); and (2) intermittent claudication (IC, Rutherford grade I–III/Fontaine stage IIa and IIb).
- exertional calf pain that does not begin at rest, does not resolve during walking activity, and resolves within 10 minutes of rest.
- For patients with intermittent claudication, a stepwise approach is recommended, providing risk factor management, best medical treatment, and exercise therapy as a first step, and revascularisation as a second step in compliant patients with continued disabling limb symptoms.
View source ↗